1
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 21:2237–2246.
2003. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy ofgefitinib, an inhibitor of the epidermal growth factor
receptor tyrosinekinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 290:2149–2158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Inoue A, Saijo Y, Maemondo M, et al:
Severe acute interstitialpneumonia and gefitinib. Lancet.
361:137–139. 2003. View Article : Google Scholar : PubMed/NCBI
|
4
|
Okamoto I, Fujii K, Matsumoto M, et al:
Diffuse alveolar damage after ZD1839 therapy in a patient with
non-small cell lung cancer. Lung Cancer. 40:339–342. 2003.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Ricciardi S, Tomao S and de Marinis F:
Toxicity of targeted therapy in non-small-cell lung cancer
management. Clin Lung Cancer. 10:28–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ando M, Okamoto I, Yamamoto N, et al:
Predictive factors for interstitial lungdisease, antitumorresponse
and survival in non-small-cell lung cancer patients treated with
gefitinib. J Clin Oncol. 24:2549–2556. 2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Luo C, Lv M, Li Y, et al:
Gefitinib-induced interstitial pneumonia: A casereport and review
of the literature. Exp Ther Med. 7:855–859. 2014.PubMed/NCBI
|
8
|
Suzuki M, Asahina H, Konishi J, Yamazaki K
and Nishimura M: Recurrent gefitinib-induced interstitial lung
disease. Intern Med. 47:533–536. 2008. View Article : Google Scholar : PubMed/NCBI
|
9
|
Takamochi K, Suzuki K, Bashar AH, et al:
Readministration of gefitinib in a responder after treatment
discontinuation due to gefinitib-related interstitial lung disease:
a case report. J Med Case Rep. 1:1382007. View Article : Google Scholar : PubMed/NCBI
|
10
|
Goto Y, Hojo M, Takeda Y, Kobayashi N and
Kudo K: Gefitinib-induced interstitial lung disease-addition of
intravenous cyclophosphamide to corticosteroids is a valuable
treatment option: A case report. Med Oncol. 27:753–755. 2010.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Seto T, Seki N, Uematsu K, et al:
Gefitinib-induced lung injury successfully treated with high-dose
corticosteroids. Respirology. 11:113–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kudoh S, Kato H, Nishiwaki Y, et al: Japan
Thoracic Radiology Group: Interstitial lung disease in Japanese
patients with lung cancer: acohort and nested case-control study.
Am J Respir Crit Care Med. 177:1348–1357. 2008. View Article : Google Scholar : PubMed/NCBI
|
13
|
Kitajima H, Takahashi H, Harada K, et al:
Gefitinib-induced interstitial lung disease showing improvement
after cessation: disassociation of serummarkers. Respirology.
11:217–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
14
|
Gillissen A: Anti-inflammatory efficacy of
N-acetylcysteine and therapeutic usefulness. Pneumologie.
65:549–557. 2011.[In German]. View Article : Google Scholar : PubMed/NCBI
|
15
|
Albera C, Ferrero C, Rindone E, Zanotto S
and Rizza E: Where do we stand with IPF treatment? Respir Res.
14(Suppl 1): S72013.PubMed/NCBI
|
16
|
Behr J and Richeldi L: Recommendations on
treatment for IPF. Respir Res. 14(Suppl 1): S62013.PubMed/NCBI
|
17
|
Idiopathic Pulmonary Fibrosis Clinical
Research Network, ; Raghu G, Anstrom KJ, King TE Jr..Lasky JA and
Martinez FJ: Prednisone, azathioprine and N-acetylcysteine for
pulmonary fibrosis. N Engl J Med. 366:1968–1977. 2012. View Article : Google Scholar : PubMed/NCBI
|